Novavax Is Poised for Renewal After Its Correction

Here's our updated analysis and trading strategy.
Stocks quotes in this article: NVAX

The last time we reviewed the charts of Novavax Inc. (NVAX) back on July 6, we wrote that, "NVAX may indeed be speculative but at this juncture in time I find no glaring reasons to be a seller. That could change at any time. Longs should risk a close below $70." We showed a $172 price target from the Point and Figure chart at that time. 

We are overdue for another review.   

In the updated daily Japanese candlestick chart of NVAX, below, we can see that prices reached our $172 price target back in late July. Prices corrected into December and then soared to new heights. NVAX corrected from early February to late March but looks ready to move higher yet again.

Prices are retesting the cresting 50-day moving average line. The slope of the 200-day moving average line is positive.

The On-Balance-Volume (OBV) line looks like it turned higher in early March telling us that buyers of NVAX are once again more aggressive. The Moving Average Convergence Divergence (MACD) oscillator is crossing above the zero line for a new outright go long signal.

 
In the weekly Japanese candlestick chart of NVAX, below, we can see a very impressive rally since early 2020. There was a lengthy correction in the back half of 2020 and another correction recently. The rising 40-week moving average line has remained unbroken the entire time.
 
The weekly OBV line has been steady since August. The MACD oscillator has corrected since February and has begun to narrow toward a new buy signal I suspect. 
 
 
In this daily Point and Figure chart of NVAX, below, we can see a potential upside price target in the $283 area. 
 
 
 
Bottom-line strategy: The weekly Point and Figure chart of NVAX does not (yet) show us an upside price target but that is expected to change if NVAX rallies to $283. Aggressive traders could go long NVAX on strength above $240.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Health Care Equipment & Services | Life Sciences | Coronavirus

More from Stocks

The Pressure Finally Lifts, but Bumpy Ride Likely Awaits

James "Rev Shark" DePorre

The sour mood suddenly lifted, and stocks enjoyed some very robust action, but that's no reason to let your guard down.

Alphabet Shares Should Continue to Live Higher

Bruce Kamich

Let's examine the charts of the 'G' in FAANG.

Will Clover Health Investments Turn Around?

Bruce Kamich

Let's take a look at 2 charts.

Hewlett Packard Enterprises Has One of Those Charts That's So Tempting

Timothy Collins

I find this to be a half now, half on a confirmed breakout play.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight